20010102
 Biovail Will Buy Right to Market Aventis Drugs   By By Mark Heinzl, The Wall Street Journal,  Jan 3, 2001  Biovail Corp. said it agreed to pay $409.5 million to Aventis Pharmaceuticals, the U.S. unit of Aventis SA, for the right to sell Aventis's Cardizem line of heart drugs in North America.  Still, shares of Biovail fell amid the stock market's broad decline yesterday. In 4 p.m New York Stock Exchange composite trading, Biovail fell $2.39, or 6.2%, to $36.45, while Aventis, based in Strasbourg, France, rose six cents to $84.31.   
